Alkermes plc (ALKS): רווח נקי למניה ב-12 החודשים האחרונים
Alkermes plc (ALKS) is driving its development vector through an active R&D pipeline focused on oncology and schizophrenia treatment. The trailing twelve-month earnings per share on the GURU.Markets chart demonstrates current cash flow stability, with the indicator standing at -0.01. This confirms the brand's authority in neurology and the effectiveness of its patented extended-release drug delivery systems, which protect profits from competition.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%90%D7%97%D7%AA%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_ALKS_-_Alkermes-plc_-_Net-earnings-per-one-share-for-the-last-twelve-months "רווח נקי למניה (EPS TTM) Alkermes plc (ALKS): לתקופה 04.07.2022 - 12.11.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Alkermes PLC (ALKS)
The specifics of Alkermes plc (ALKS) necessitate significant expenditures for the specialized transportation of psychotropic agents, which directly impacts final margins. By analyzing the net earnings per share over the last four quarters, an investor sees the result of dividing the total annual income by the number of shares, which allows for an assessment of the business's real yield without time lags and determines the degree of the asset's overvaluation.
